SCRI Development Innovations, LLC

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer
Cancer of the Rectum
Colorectal Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Bevacizumab
Procedure: Radiation Therapy
Drug: Oxaliplatin
Drug: Leucovorin

First Posted Date: 2006-03-29

Last Posted Date: 2021-12-10

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 66

Registration Number: NCT00308516

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States

and more 11 locations

Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Small Cell

Interventions: Drug: Topotecan
Drug: carboplatin

First Posted Date: 2006-03-22

Last Posted Date: 2013-01-31

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 61

Registration Number: NCT00305942

Locations: 🇺🇸
Family Cancer Center, Collierville, Tennessee, United States
🇺🇸
Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸
Montana Cancer Institute Foundation, Missoula, Montana, United States

and more 13 locations

Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Oxaliplatin

First Posted Date: 2006-02-28

Last Posted Date: 2021-10-28

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 25

Registration Number: NCT00297596

Locations: 🇺🇸
Graves-Gilbert Clinic, Bowling Green, Kentucky, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States

and more 4 locations

Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Small Cell Lung

First Posted Date: 2006-02-22

Last Posted Date: 2010-06-28

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 50

Registration Number: NCT00294931

Locations: 🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

and more 1 locations

Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer
Carcinoma, Small Cell

Interventions: Drug: Topotecan

First Posted Date: 2006-02-20

Last Posted Date: 2012-12-10

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 38

Registration Number: NCT00294190

Locations: 🇺🇸
Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States
🇺🇸
Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States
🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States

and more 10 locations

Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Small Cell
Lung Cancer

Interventions: Drug: Vinflunine

First Posted Date: 2006-01-31

Last Posted Date: 2013-03-13

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 51

Registration Number: NCT00284154

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States

Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Neoplasms
Breast Cancer

Interventions: Drug: Vinflunine
Drug: Trastuzumab

First Posted Date: 2006-01-31

Last Posted Date: 2013-08-09

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 32

Registration Number: NCT00284180

Locations: 🇺🇸
Associates in Hematology Oncology, Chattanooga, Tennessee, United States
🇺🇸
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 7 locations

Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

Phase 2

Completed

Conditions: Neuroendocrine Carcinoma

First Posted Date: 2005-09-19

Last Posted Date: 2023-04-11

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 100

Registration Number: NCT00193531

Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2011-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 40

Registration Number: NCT00193102

Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2015-12-10

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 60

Registration Number: NCT00193089

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy